Congenital enterocyte heparan sulfate deficiency is a real but ultra-rare genetic intestinal disease. It causes the small-intestine lining cells, called enterocytes, to lack heparan sulfate on their basolateral surface. In reported infants, this leads to very early severe secretory diarrhea, loss of protein into the gut, poor tolerance of feeds, swelling from low albumin, and malnutrition. The published evidence is very limited, so most treatment is supportive rather than disease-specific.
Congenital enterocyte heparan sulfate deficiency is a very rare, severe, genetic intestinal disease. In this condition, the small bowel lining cells, called enterocytes, do not show normal heparan sulfate on their basolateral surface. Heparan sulfate helps the bowel wall act like a filter and barrier. When it is missing, protein and fluid can leak from the intestine into the bowel lumen. This can lead to secretory diarrhea, protein loss, poor feeding, and malnutrition very early in life, usually in the newborn or infant period. The published medical literature is very small, so some details are known well, while other details are based on rare-disease databases and broader reviews of congenital diarrheal disorders. [1][2][3]
Another names
This disease is also called congenital enterocyte heparan sulphate deficiency using British spelling. Some rare-disease sources also describe it as congenital intestinal heparan sulfate deficiency or use the short form CEHSD. These names all point to the same idea: a baby is born with abnormal or absent heparan sulfate in the intestinal epithelial cells. [1][2][4]
Types
There are no widely accepted formal subtypes for this disease in the current literature. Doctors usually describe cases by age of onset, severity, and whether the baby mainly shows secretory diarrhea, massive protein loss, or feeding intolerance. A practical way to describe the pattern is: neonatal-onset form, early-infant-onset form, protein-losing dominant form, and mixed severe enteropathy form. This is a clinical way of describing patients, not an official classification system. [1][2][5]
Causes
The main cause is believed to be a genetic defect present from birth that leads to absence or major reduction of heparan sulfate on intestinal enterocytes. Rare-disease sources clearly describe it as a genetic intestinal disease, but the exact disease gene has not been well defined in the small amount of published case literature available. [1][2]
1. Inherited pathogenic genetic change. A harmful DNA change present from birth is the most likely root cause. This can disturb how enterocytes build or keep heparan sulfate on their surface. [1][2]
2. Autosomal recessive inheritance is suspected in some congenital enteropathies. In rare infant bowel diseases, recessive inheritance is common, especially when siblings are affected or parents are related by blood. This is a risk pattern doctors look for, even though it is not proven for every CEHSD case. [5][6]
3. De novo mutation. Sometimes a baby may develop a new genetic change that was not seen in the parents. This is a possible explanation in rare monogenic intestinal disorders. [2][5]
4. Defect in heparan sulfate biosynthesis. The body must build heparan sulfate in several steps. A defect in any step can lower the final amount on the cell surface. This is a biologically strong explanation for the disease. [1][7]
5. Defect in glycosylation pathways. Related research shows that some congenital disorders of glycosylation can reduce heparan sulfate accumulation in enterocytes and cause protein-losing enteropathy. This is not the same disease in every case, but it supports the mechanism. [7][8]
6. Abnormal sulfation of glycosaminoglycans. Heparan sulfate must be properly sulfated to work well. Poor sulfation can weaken the bowel barrier. [7][9]
7. Defective basolateral membrane expression. The classic description says the missing heparan sulfate is found on the basolateral surface of enterocytes. So a defect in placing the molecule in the correct cell area may be part of the cause. [1][3]
8. Defect in proteoglycan anchoring. Heparan sulfate is attached to core proteins, such as syndecans. If anchoring is abnormal, the bowel wall can lose its barrier function. [7][9]
9. Syndecan-1 related abnormality. Research in related protein-losing enteropathy shows reduced syndecan-1 and heparan sulfate together in enterocytes. This suggests that abnormal syndecan-1 biology may contribute in some patients. [7][9]
10. Basement membrane barrier defect. The enterocyte basement membrane helps stop protein leakage. If heparan sulfate is absent there, albumin can escape into the intestine. [9][10]
11. Congenital epithelial differentiation defect. Reviews of congenital enteropathies explain that some babies are born with abnormal enterocyte structure or differentiation. CEHSD fits inside that broad group of congenital epithelial diseases. [5][11]
12. Congenital epithelial polarity defect. Enterocytes must keep apical and basolateral sides separate. When polarity is abnormal, essential surface molecules may be misplaced. This is a known mechanism in related congenital enteropathies. [5]
13. Defective extracellular matrix interaction. Heparan sulfate normally helps cells interact with the surrounding matrix. If this support system fails, intestinal permeability may rise. [9][12]
14. Increased intestinal permeability from birth. A weak barrier allows water, salts, and proteins to move abnormally into the gut. This can explain secretory diarrhea and albumin loss. [3][10]
15. Family history of similar neonatal diarrhea. This does not directly cause the disease, but it strongly raises suspicion for a congenital genetic cause. [5][11]
16. Consanguinity of parents. In congenital enteropathies, parental relatedness can increase the chance that a baby inherits two abnormal copies of a rare gene. [5][6]
17. Prenatal developmental error in intestinal epithelial biology. Because symptoms begin very early, the abnormality likely starts during fetal development of the intestinal lining. [1][2]
18. Monogenic congenital diarrheal disorder background. Reviews group these diseases as monogenic disorders that cause severe early diarrhea, poor growth, and intestinal failure. CEHSD is part of that broad disease family. [11][13]
19. Congenital disorder of glycosylation associated enterocyte heparan sulfate loss. Some children with glycosylation disorders develop reduced enterocyte heparan sulfate and protein-losing enteropathy, so this is an important related cause pattern doctors consider in the differential diagnosis. [7][8]
20. Unknown gene or not-yet-identified molecular defect. Because the disease is so rare and only a few reports exist, some cases may remain genetically unsolved even after testing. [1][2][11]
Symptoms
1. Severe watery diarrhea. This is the best known symptom. The diarrhea is usually persistent and can be very heavy because the bowel secretes fluid abnormally. [1][3]
2. Secretory diarrhea that continues despite feeding changes. In secretory diarrhea, stool loss may continue even when feeding is reduced, because the bowel itself is leaking fluid and salts. [1][11]
3. Intolerance to enteral feeds. Many infants cannot tolerate milk or tube feeds well. Symptoms worsen soon after feeding. [1][4]
4. Massive enteric protein loss. Important blood proteins, especially albumin, are lost through the intestine. This is one of the hallmark features. [1][3]
5. Hypoalbuminemia. Blood albumin becomes low because it leaks into stool. Low albumin can make the child weak and swollen. [3][14]
6. Swelling or edema. Low albumin can cause puffiness of the feet, legs, face, or whole body because fluid moves out of blood vessels. [14]
7. Malnutrition. Constant diarrhea and protein loss stop the baby from getting enough nutrition for normal growth. [1][3]
8. Poor weight gain or failure to thrive. Babies may not gain weight well and may fall behind normal growth curves. [11][13]
9. Dehydration. Heavy stool losses can remove a large amount of water, leading to dry mouth, poor tears, low urine, and sleepiness. [11][13]
10. Electrolyte imbalance. Sodium, potassium, and bicarbonate can become abnormal because of ongoing stool loss. [11][13]
11. Weakness and tiredness. The baby may become weak from poor nutrition, dehydration, and low protein. [3][14]
12. Irritability. Sick infants often become unusually fussy because of hunger, dehydration, abdominal discomfort, and weakness. [11][13]
13. Abdominal bloating or distension. Some infants develop a swollen belly as part of severe intestinal disease or poor feeding tolerance. [11][13]
14. Need for parenteral nutrition. Many severe congenital enteropathies become so serious that the child needs nutrition through a vein for survival and growth. [5][11]
15. Early presentation in newborn or infancy. The timing itself is an important clinical clue. Symptoms often begin in the first weeks or months of life. [1][2]
Diagnostic tests
Doctors do not usually diagnose this disease with one single test. They use a step-by-step work-up for congenital diarrhea and protein-losing enteropathy. The diagnosis becomes more likely when a baby has very early diarrhea, feed intolerance, protein loss, and biopsy evidence of absent enterocyte heparan sulfate after other causes are excluded. [1][11][14]
Growth and weight check. Doctors look for poor weight gain, low body fat, and failure to thrive, which suggest chronic severe bowel disease. [11][13]
Dehydration assessment. Dry mouth, sunken eyes, low urine, and poor skin turgor suggest major fluid loss from diarrhea. [11][13]
Edema check. Swelling of the feet, eyelids, or body can point to low albumin from protein-losing enteropathy. [14]
Abdominal examination. The doctor checks for distension, tenderness, bowel sounds, and signs of malnutrition. [11]
Stool history and feed-response assessment. Doctors carefully ask whether diarrhea starts right after birth, whether it continues during fasting, and whether feeds make it worse. This helps separate congenital secretory diarrhea from other causes. [11][15]
Family pedigree review. A family tree may show affected siblings, infant deaths, or parental consanguinity, which support a genetic cause. [5][11]
Diet trial observation. Doctors may observe whether symptoms improve or do not improve when feeds are changed. Persistent stool loss suggests a congenital enteropathy. [11][15]
Intake-output monitoring. Careful measurement of what goes in and what comes out helps show how severe the fluid and stool loss is. [11][13]
Serum albumin. A low albumin level is one of the most important clues because this disorder causes heavy enteric protein loss. [1][14]
Total protein level. Low total protein supports the idea that the child is losing protein through the bowel. [14]
Stool alpha-1 antitrypsin or alpha-1 antitrypsin clearance. This is a key test for protein-losing enteropathy because high stool loss of this protein strongly supports intestinal protein leakage. [14][16]
Electrolyte panel. Sodium, potassium, chloride, and bicarbonate are measured to judge the effect of severe diarrhea and to guide urgent treatment. [11][13]
Blood gas and acid-base testing. Severe diarrhea may cause metabolic acidosis or other chemical imbalance. [11][13]
Stool electrolytes and osmotic gap analysis. These tests help decide whether the diarrhea is secretory or osmotic, which is very useful in congenital diarrhea work-ups. [17]
Infection stool tests. Stool culture, viral testing, and parasite testing help rule out more common infectious causes before a rare congenital diagnosis is made. [11][17]
Endoscopy with small-bowel biopsy. This is one of the most important tests. In CEHSD, routine biopsy may look mostly normal, but tissue staining can show absent heparan sulfate on the enterocyte basolateral surface. [1][3]
Immunohistochemistry for heparan sulfate. Special staining of biopsy tissue can directly show the lack of enterocyte heparan sulfate, which is the key pathological sign. [1][3]
Genetic testing panel or exome sequencing. Because congenital diarrheal disorders are usually monogenic, molecular testing is a major part of diagnosis, even if a specific gene is not found in every case. [11][17]
Intestinal manometry in selected cases. This is not specific for CEHSD, but it can help when doctors need to separate epithelial disease from severe motility disorders. [11][13]
Electrogastrography or other motility-related functional studies in selected centers. These are supportive tests only. They are mainly used when the diagnosis is uncertain and other causes of chronic severe diarrhea are being excluded. [11][13]
Imaging tests can also support diagnosis, although they do not prove CEHSD by themselves. Abdominal ultrasound checks for bowel complications and other organ problems. Contrast studies can help rule out structural disease. Chest or abdominal imaging may also be used when severe malnutrition, edema, or complications are present. Nuclear medicine protein-loss scans are sometimes used in protein-losing enteropathy, but stool alpha-1 antitrypsin testing is often more practical. [14][18]
Non-Pharmacological Treatments
- Intestinal rehabilitation program. This is the most important non-drug treatment. A specialized team watches growth, hydration, stool loss, liver health, line care, and feeding tolerance over time. The purpose is to keep the child alive, nourished, and growing while lowering complications. The mechanism is careful long-term adjustment of nutrition, fluids, and supportive care based on symptoms and lab results.
- Parenteral nutrition. Many affected infants cannot absorb enough fluid, energy, protein, vitamins, and minerals through the gut. Parenteral nutrition gives these nutrients directly into the bloodstream. Its purpose is growth and survival. The mechanism is bypassing the injured intestinal barrier when enteral feeding causes severe diarrhea or protein loss.
- Individualized enteral feeding trials. Small, careful feed trials may still be used because some bowel stimulation can help adaptation, even when full feeding is not possible. The purpose is to find the safest tolerated intake. The mechanism is gradual testing of volume, timing, and formula type while monitoring stool output, edema, and weight.
- Specialized formula selection. Some congenital enteropathies do better with hydrolyzed, amino-acid, or specially restricted formulas. This disorder has no single proven formula, but formula choice is often tailored. The purpose is to reduce diarrhea and improve absorption. The mechanism is lowering exposure to nutrients that worsen osmotic load or poor intestinal handling.
- Strict fluid and electrolyte replacement. Severe diarrhea can quickly cause dehydration, sodium loss, potassium loss, and acid-base imbalance. The purpose is to protect the brain, kidneys, and circulation. The mechanism is replacing exactly what is lost in stool, urine, and vomiting, often with frequent blood-test guidance.
- High-protein nutritional strategy. Because protein leaks into the intestine, many children need more protein than usual. The purpose is to raise albumin and support growth. The mechanism is giving more protein through parenteral nutrition or tolerated feeds to offset gut protein loss.
- Fat-soluble vitamin replacement planning. Chronic diarrhea and intestinal failure can reduce absorption of vitamins A, D, E, and K. The purpose is to prevent bleeding, weak bones, poor vision, and nerve problems. The mechanism is routine monitoring and replacement through enteral or parenteral routes.
- Central line care bundles. Children dependent on parenteral nutrition often need long-term central venous access. The purpose is to prevent bloodstream infection and line failure. The mechanism is sterile handling, dressing care, and standardized protocols at home and in hospital.
- Liver-protection strategies during PN. Long-term PN can injure the liver. The purpose is to reduce cholestasis and liver failure. The mechanism includes balanced lipid choice, careful calorie delivery, cycling PN when appropriate, and close liver-test monitoring.
- Regular growth monitoring. Weight, length, head growth, and body composition should be followed closely. The purpose is to catch undernutrition early. The mechanism is adjusting calories, protein, and fluid before severe growth failure develops.
- Routine stool and symptom tracking. Families often record stool volume, number of stools, vomiting, edema, and feed tolerance. The purpose is to see whether treatment changes help or harm. The mechanism is turning daily symptoms into practical clinical data.
- Albumin-loss monitoring. Protein-losing enteropathy can cause low albumin, swelling, and effusions. The purpose is to guide nutrition and supportive treatment. The mechanism is repeated albumin, total protein, and sometimes stool alpha-1 antitrypsin measurement.
- Micronutrient surveillance. Iron, zinc, selenium, copper, magnesium, and other trace nutrients may fall in chronic intestinal failure. The purpose is to prevent anemia, poor immunity, skin problems, and poor growth. The mechanism is scheduled laboratory review and targeted replacement.
- Edema management with nutrition-first thinking. Swelling is often a sign of low blood protein, not just excess water. The purpose is to improve comfort and circulation. The mechanism is correcting protein loss and nutrition rather than only restricting fluids.
- Home PN education. Families need training in pump use, mixing safety, line flushing, and emergency response. The purpose is safe long-term care outside hospital. The mechanism is reducing errors, infection, and treatment interruption.
- Multidisciplinary developmental support. Infants with long hospital stays can develop feeding delay, oral aversion, and delayed milestones. The purpose is better long-term quality of life. The mechanism is involving developmental therapists, feeding therapists, and social support early.
- Early genetic diagnosis. In congenital diarrheal disorders, molecular diagnosis helps confirm cause and guide counseling. The purpose is diagnostic clarity and family planning. The mechanism is identifying the responsible genetic defect in a monogenic enteropathy pattern.
- Infection prevention. Children with central lines and malnutrition are vulnerable to infection. The purpose is to avoid sepsis and hospitalization. The mechanism is vaccination, line hygiene, early fever response, and minimizing unnecessary exposure.
- Referral to transplant center when needed. If intestinal failure becomes irreversible and serious PN complications develop, transplant evaluation may be necessary. The purpose is rescue therapy. The mechanism is replacing the failing intestine, sometimes with liver if needed.
- Family counseling and long-term care planning. This disease is emotionally and physically demanding. The purpose is safe adherence and realistic decision-making. The mechanism is repeated education about prognosis, complications, nutrition plans, and emergency signs.
Drug Treatments
Because no drug is approved specifically for this disease, the medicines below are supportive examples used for related problems under specialist supervision. Exact infant dosing is individualized.
- Teduglutide. This GLP-2 analog is FDA-approved for adults and children age 1 year and older with short bowel syndrome who depend on parenteral support. It is not approved specifically for this disorder, but in intestinal failure it may reduce PN need in selected patients. Its purpose is gut rehabilitation. Its mechanism is improving mucosal growth and absorption. FDA label dose is 0.05 mg/kg once daily subcutaneously. Risks include abdominal pain, fluid overload, and intestinal obstruction concerns.
- Octreotide. Octreotide is FDA-approved for severe secretory diarrhea in carcinoid syndrome and VIPoma, not for this disease. Still, some clinicians may consider it off-label when diarrhea is extreme. Its purpose is to lower stool loss. The mechanism is reducing gastrointestinal hormone secretion and fluid secretion. Side effects include gallstones, glucose changes, and abdominal symptoms.
- Loperamide. Loperamide is FDA-approved for symptomatic control of diarrhea, though disease-specific pediatric use in this rare condition must be specialist-led. Its purpose is slower gut transit and lower stool volume. The mechanism is peripheral opioid receptor action in the bowel. Side effects can include ileus, constipation, and dangerous heart rhythm problems in overdose.
- SMOFlipid. This FDA-approved lipid emulsion is used in PN when oral or enteral nutrition is not possible, insufficient, or contraindicated. Its purpose is calorie and essential fatty acid delivery. The mechanism is intravenous provision of fat needed for growth and energy. It helps support children who cannot absorb enough nutrition through the intestine.
- Omegaven. Omegaven is FDA-approved as a source of calories and fatty acids in pediatric patients with PN-associated cholestasis. In PN-dependent infants with liver complications, it may be used to support nutrition while limiting progression of PN-related liver injury. It is not a cure for the intestinal disease itself.
- Ursodiol. Ursodiol is FDA-approved for cholestatic liver conditions, not for congenital enterocyte heparan sulfate deficiency. In practice, it may be used if PN-related cholestasis develops. Its purpose is to improve bile flow. The mechanism is making bile less toxic and helping bile movement.
- Intravenous iron products. Iron deficiency can happen in chronic intestinal disease and protein loss. FDA-approved IV iron products are used when oral iron is not tolerated or ineffective. Their purpose is anemia correction. Their mechanism is direct iron replacement into the bloodstream. Choice and dose depend on age, weight, iron studies, and product label.
- Albumin infusion. Human albumin is not disease-specific therapy, but it may be used temporarily in severe hypoalbuminemia with edema or circulatory compromise. Its purpose is short-term plasma protein replacement. The mechanism is increasing oncotic pressure in the bloodstream. It does not stop the intestinal loss, so nutrition treatment is still essential.
- Vitamin K and other parenteral vitamin products. These are supportive drugs used when malabsorption or PN dependence causes deficiency. Their purpose is prevention of bleeding, bone disease, and nerve problems. The mechanism is replacing vitamins that cannot be absorbed reliably through the gut.
- Antibiotics for catheter-related infection. These are not routine disease drugs, but they are often life-saving when line sepsis occurs. Their purpose is infection control. The mechanism is targeted treatment against bloodstream pathogens while preserving line function when possible. Drug choice must follow culture results and hospital protocols.
Dietary and Molecular Supplements
- Protein supplementation may be needed because protein is lost into the gut.
- Zinc can support growth and skin healing.
- Iron may correct iron deficiency.
- Vitamin D supports bones.
- Calcium supports bones and muscle function.
- Vitamin A supports vision and immunity.
- Vitamin E supports nerves and cell protection.
- Vitamin K helps blood clotting.
- Selenium supports antioxidant systems.
- Magnesium supports nerves, muscle, and fluid balance. In this disease, supplements should be chosen by blood tests because both deficiency and excess can be harmful.
6 Immunity, Regenerative, or Stem Cell Drug Points
- There is no proven immunity booster that treats this disease directly.
- There is no FDA-approved regenerative medicine drug for this disorder.
- There is no FDA-approved stem-cell drug for this exact condition.
- Teduglutide is the closest gut-rehabilitation drug in intestinal failure, but it is not a stem-cell treatment.
- Intestinal transplant is a surgical rescue option, not a drug.
- Experimental future directions may include gene-based or regenerative approaches, but current care remains supportive.
Surgeries or Procedures
- Central venous catheter placement is often necessary for long-term PN. 2) Catheter revision or replacement may be needed if infection or blockage occurs. 3) Feeding tube placement may help with controlled enteral trials in selected patients. 4) Intestinal transplantation is considered for irreversible intestinal failure with major PN complications. 5) Combined liver-intestine transplant may be needed when intestinal failure and liver failure occur together. These are done to maintain nutrition access or rescue life-threatening complications.
Prevention Points
This disease itself is congenital, so it usually cannot be prevented after conception. Prevention mainly means preventing complications. Important steps are: 1) early diagnosis, 2) genetic counseling for families, 3) rapid dehydration treatment, 4) careful PN monitoring, 5) line infection prevention, 6) liver-protection strategies, 7) regular growth checks, 8) micronutrient monitoring, 9) early referral to intestinal rehabilitation teams, and 10) timely transplant assessment if complications increase.
When to See Doctors Urgently
Urgent medical review is needed for fever, poor feeding, new swelling, reduced urine, severe diarrhea increase, blood in stool, repeated vomiting, breathing trouble, central-line redness, or sudden sleepiness. These can mean dehydration, sepsis, severe electrolyte imbalance, or worsening hypoalbuminemia.
What to Eat and What to Avoid
Food plans must be individualized, but general ideas are: 1) use only formulas advised by the specialist team, 2) avoid random diet changes, 3) avoid high-osmolar sugary drinks, 4) avoid unplanned herbal products, 5) use protein support if prescribed, 6) use vitamin and mineral supplements only when advised, 7) keep hydration plans exact, 8) prefer sterile and safely prepared feeds, 9) do not force large feed volumes, and 10) review every new food with the care team if the child is feed-sensitive. In severe disease, much of the nutrition may come from PN rather than normal eating.
FAQs
1. Is this a real disease? Yes. It is listed by rare-disease resources and described in the literature.
2. Is it common? No. It is extremely rare.
3. When does it start? Usually in the newborn or early infant period.
4. What are the main problems? Severe diarrhea, protein loss, feed intolerance, and malnutrition.
5. Is there a cure? No established cure is available now.
6. Can normal feeding cure it? Usually not by itself in severe cases. Many infants need PN.
7. Are there disease-specific FDA drugs? No. Treatment is mainly supportive.
8. Can teduglutide help? Sometimes it may help selected intestinal failure patients, but it is not approved specifically for this disease.
9. Can octreotide stop the diarrhea? It may be considered off-label in some secretory diarrhea settings, but evidence in this exact disorder is limited.
10. Why does swelling happen? Protein leaks into the gut, lowering blood albumin.
11. Why is the liver monitored? Long-term PN can cause cholestasis and liver injury.
12. Can transplant be needed? Yes, if intestinal failure is irreversible and major PN complications develop.
13. Are stem cells standard treatment? No. Not for this disease.
14. Should families get genetic counseling? Yes, because it is a congenital genetic disorder.
15. What kind of doctor is best? A pediatric gastroenterologist with an intestinal rehabilitation center is best.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: April 02, 2025.
